Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study

American Journal of Epidemiology

Volumn 172, Issue 9, 2010, Pages 1028-1033

  Rebora, Paola ^a   Czene, Kamila ^b   Antolini, Laura ^a   Passerini, Carlo Gambacorti ^a   Reilly, Marie ^b   Valsecchi, Maria Grazia ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

interferons; leukemia, myelogenous, chronic, BCR ABL positive; neoplasms, second primary; registries; survival

Indexed keywords

ALPHA INTERFERON; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ASSESSMENT METHOD; CANCER; DATA SET; DISEASE TREATMENT; FUNCTIONAL MORPHOLOGY; INHIBITOR; POPULATION STRUCTURE; RISK FACTOR; STANDARDIZATION; SURVIVAL;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CHRONIC DRUG ADMINISTRATION; CHRONIC MYELOID LEUKEMIA; FEMALE; HIGH RISK PATIENT; HUMAN; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PROGNOSIS; SECOND CANCER; SKIN CANCER; STOMACH CANCER; SWEDEN; UROGENITAL TRACT CANCER;

FEMALE; HUMANS; INCIDENCE; LEUKEMIA, LYMPHOID; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS; STOMACH NEOPLASMS; SURVIVAL RATE; SWEDEN; UROGENITAL NEOPLASMS;

SWEDEN;

EID: 77958587566     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq262     Document Type: Article

References (25)

1. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic mye-logenous leukemia. N Engl J Med. 2002;346(9):645-652. (Pubitemid 34815868)
2. Palandri F, Iacobucci I, Castagnetti F, et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. Haematolog-ica. 2008;93(5):770-774.
3. Kantarjian H, O'Brien S, Cortes J, et al. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer. 2008;113(7 suppl):1933-1952.
4. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348(11):994-1004.
5. Aziz Z, Iqbal J, Akram M, et al. Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country. Cancer. 2007;109(6):1138-1145.
6. Palandri F, Castagnetti F, Alimena G, et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica. 2009;94(2):205-212.
7. Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic mye-loid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol. 2003; 21(11):2138-2146.
8. Boivin JF. Second cancers and other late side effects of cancer treatment. A review. Cancer. 1990;65(3 suppl):770-775. 9.
9. Roy L, Guilhot J, Martineau G, et al. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia. 2005;19(9):1689-1692.
10. Talpaz M, Kantarjian HM, McCredie K, et al. Hematologic remission and cytogenetic improvement induced by recombi-nant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 1986;314(17):1065-1069.
11. Dow LW, Raimondi SC, Culbert SJ, et al. Response to alpha-interferon in children with Philadelphia chromosome-positive chronic myelocytic leukemia. Cancer. 1991;68(8):1678-1684.
12. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994;84(12):4064-4077.
13. Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer. 2001;85(7):997-1005.
14. Curtis R, Freedman D, Ron E, et al. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD: National Cancer Institute; 2006.
15. Miettinen M, Kraszewska E, Sobin LH, et al. A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia. Cancer. 2008;112(3):645-649.
16. Gambacorti-Passerini C, Kim D-W, Mahon F-X, et al. Imati-nib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients. San Francisco, CA: Moscone Center; 2008.
17. Lucas CM, Wang L, Austin GM, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia. 2008;22(10): 1963-1966.
18. Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol. 1984;23(5):305-313.
19. Breslow NE, Day NE, eds. Statistical Methods in Cancer Research. Vol 2. The Design and Analysis of Cohort Studies. (IARC Scientific Publication no. 82). Lyon, France: International Agency for Research on Cancer; 1987.
20. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6: 101-121.
21. Dickman PW, Sloggett A, Hills M, et al. Regression models for relative survival. Stat Med. 2004;23(1):51-64.
22. Fausel C. Targeted chronic myeloid leukemia therapy: seeking a cure. J Manag Care Pharm. 2007;13(8 suppl A): 8-12.
23. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054-1061.
24. Cortes JE. Imatinib therapy for chronic myeloid leukemia: where do we go now? J Clin Oncol. 2008;26(20):3308-3309.
25. Begg CB, Zhang ZF, Sun M, et al. Methodology for evaluating the incidence of second primary cancers with application to smoking-related cancers from the Surveillance, Epidemiology, and End Results (SEER) program. Am J Epidemiol. 1995; 142(6):653-665.